Low-Temperature Vaporizer Formulation for Medicant Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods of drug administration, particularly inhalation, often result in slow onset of action, inactivation of medications in the digestive tract, and side effects due to high-temperature vaporization, which can alter the chemical structure of medicants or excipients, necessitating improved routes that preserve the integrity of active ingredients and allow for precise dosing.
Innovation Solution
A formulation combining an excipient with a low vaporization temperature and an active ingredient of higher vaporization temperature, where the excipient acts as a carrier to vaporize the active ingredient at a lower temperature, ensuring precise and effective delivery via inhalation without damaging the medicant or excipient.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high-temperature vaporization is used to deliver medicants via inhalation, then the medicant can be delivered to the user, but the chemical structure of the medicant or excipient may be altered or destroyed
Solution Approach 1:
The patent changes the temperature parameter from high-temperature vaporization to low-temperature vaporization. The excipient is specifically selected to have a low vaporization temperature (below 100°C), allowing the medicant to be delivered via inhalation without exposing it to high temperatures that would alter or destroy its chemical structure.
Solution Approach 2:
The excipient acts as an intermediary carrier substance. It forms a composition with the medicant and vaporizes at low temperatures, carrying the medicant through inhalation delivery without requiring the medicant itself to undergo high-temperature vaporization, thus protecting the medicant's chemical integrity.
2Ease of operation
If oral administration is used to deliver medication, then the drug can be delivered to the user, but the onset of activation is slow and the drug may be inactivated or destroyed in the digestive tract
Solution Approach 1:
The patent replaces the gastrointestinal digestive system with the respiratory inhalation system. Instead of the drug passing through the digestive tract where it may be inactivated or slowly absorbed, the vaporized medicant is delivered directly to the lungs and enters the bloodstream rapidly through pulmonary absorption, achieving quick onset of action while maintaining ease of administration.
3Reliability
If the excipient vaporization temperature is lowered to preserve medicant integrity, then the medicant chemical structure is maintained, but precise dosing becomes more challenging
Solution Approach 1:
The excipient composition is formulated to vaporize at a specific low temperature range, and the vaporization process itself provides self-regulating dosing. The controlled vaporization of the excipient-carrier system delivers a consistent amount of medicant with each inhalation, achieving precise dosing through the inherent properties of the low-temperature vaporization system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the efficient and precise delivery of medicants as vaporized active ingredients, minimizing side effects and maintaining their chemical structure, providing quick and effective relief with reduced risk of over-dosing and gastrointestinal distress.
Implementation Method 1
an excipient with a low vaporization temperature may be combined with an active ingredient that may have a higher vaporization temperature. When the combination is heated to a temperature sufficient to vaporize the excipient, the excipient vapor carries molecules of the active ingredient along with it.
Data Source
AI summary
A method and formulation for delivering an active analgesic compound, such as an opiate, in a vaporized state using low temperatures to vaporize the formulation. The formulation contains an inert non-reactive compound that lowers the heat of vaporization of the formulation, and the active compound. The formulation may optionally contain glycerin, alcohol, and/or water. Examples of inert non-reactive compounds that can sufficiently lower the heat of vaporization of the formulation include propylene glycol, vegetable glycerin and polysorbate. The formulation can be vaporized using a hand-held low temperature vaporizer or atomizer.